Further follow-up of these MCI-NC patients and the development of an integrated biomarker model to assess amyloid and tau PET examinations, along with FDG-PET, for the early detection of MCI conversion to dementia, could hold clinical significance [68, 69]. The gene discussed is MAPT; the disease is dementia.